| Autor: |
Gerotziafas, G.T. Catalano, M. Colgan, M.-P. Pecsvarady, Z. Wautrecht, J.C. Fazeli, B. Olinic, D.-M. Farkas, K. Elalamy, I. Falanga, A. Fareed, J. Papageorgiou, C. Arellano, R.S. Agathagelou, P. Antic, D. Auad, L. Banfic, L. Bartolomew, J.R. Benczur, B. Bernardo, M.B. Boccardo, F. Cifkova, R. Cosmi, B. De Marchi, S. Dimakakos, E. Dimopoulos, M.A. Dimitrov, G. Durand-Zaleski, I. Edmonds, M. El Nazar, E.A. Erer, D. Esponda, O.L. Gresele, P. Gschwandtner, M. Gu, Y. Heinzmann, M. Hamburg, N.M. Hamadé, A. Jatoi, N.-A. Karahan, O. Karetova, D. Karplus, T. Klein-Weigel, P. Kolossvary, E. Kozak, M. Lefkou, E. Lessiani, G. Liew, A. Marcoccia, A. Marshang, P. Marakomichelakis, G. Matuska, J. Moraglia, L. Pillon, S. Poredos, P. Prior, M. Salvador, D.R.K. Schlager, O. Schernthaner, G. Sieron, A. Spaak, J. Spyropoulos, A. Sprynger, M. Suput, D. Stanek, A. Stvrtinova, V. Szuba, A. Tafur, A. Vandreden, P. Vardas, P.E. Vasic, D. Vikkula, M. Wennberg, P. Zhai, Z. Bikdeli, B. Guo, Y. Harenberg, J. Hu, Y. Lip, G.Y.H. Roldan, V. |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Popis: |
COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH. © 2020 Georg Thieme Verlag. All rights reserved. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
